Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Thompson

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|August 5, 2008
Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trialWilliam Kemp, John Colman, Kenneth Thompson, et al.
Plos One|December 20, 2014
Dexpramipexole is ineffective in two models of ALS related neurodegenerationFernando G Vieira, Eva LaDow, Andy Moreno, et al.
Journal of Agricultural and Food Chemistry|November 28, 2002
Flunixin residues in milk after intravenous treatment of dairy cattle with (14)C-flunixinWilliam F Feely, Cheryl Chester-Yansen, Kenneth Thompson, et al.
IBRO Reports|August 24, 2018
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefitsFernando G Vieira, Theo Hatzipetros, Kenneth Thompson, et al.
Transactions of the American Ophthalmological Society|May 2, 2007
Reduction of preoperative conjunctival bacterial flora with the use of mupirocin nasal ointmentTerry J Alexandrou, Seenu M Hariprasad, Joseph Benevento, et al.
Neurobiology of Disease|June 5, 2025
Comprehensive characterization and validation of the Prp-hPFN1<sup>G118V</sup> mouse model: Guidelines for preclinical therapeutic testing for ALSKaly A Mueller, Emma G Suneby, Matthew H Ferola, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|February 15, 2008
Design, power, and interpretation of studies in the standard murine model of ALSSean Scott, Janice E Kranz, Jeff Cole, et al.
Scientific Reports|May 2, 2019
SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALSCindy Gill, James P Phelan, Theo Hatzipetros, et al.
Plos One|August 20, 2015
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALSFernando G Vieira, Qinggong Ping, Andy J Moreno, et al.
Nature Genetics|March 30, 2010
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosisJohn M Lincecum, Fernando G Vieira, Monica Z Wang, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Liver International : Official Journal of the International Association for the Study of the Liver|August 5, 2008
Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trialWilliam Kemp, John Colman, Kenneth Thompson, et al.
Plos One|December 20, 2014
Dexpramipexole is ineffective in two models of ALS related neurodegenerationFernando G Vieira, Eva LaDow, Andy Moreno, et al.
Journal of Agricultural and Food Chemistry|November 28, 2002
Flunixin residues in milk after intravenous treatment of dairy cattle with (14)C-flunixinWilliam F Feely, Cheryl Chester-Yansen, Kenneth Thompson, et al.
IBRO Reports|August 24, 2018
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefitsFernando G Vieira, Theo Hatzipetros, Kenneth Thompson, et al.
Transactions of the American Ophthalmological Society|May 2, 2007
Reduction of preoperative conjunctival bacterial flora with the use of mupirocin nasal ointmentTerry J Alexandrou, Seenu M Hariprasad, Joseph Benevento, et al.
Neurobiology of Disease|June 5, 2025
Comprehensive characterization and validation of the Prp-hPFN1<sup>G118V</sup> mouse model: Guidelines for preclinical therapeutic testing for ALSKaly A Mueller, Emma G Suneby, Matthew H Ferola, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|February 15, 2008
Design, power, and interpretation of studies in the standard murine model of ALSSean Scott, Janice E Kranz, Jeff Cole, et al.
Scientific Reports|May 2, 2019
SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALSCindy Gill, James P Phelan, Theo Hatzipetros, et al.
Plos One|August 20, 2015
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALSFernando G Vieira, Qinggong Ping, Andy J Moreno, et al.
Nature Genetics|March 30, 2010
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosisJohn M Lincecum, Fernando G Vieira, Monica Z Wang, et al.
Pageof 4